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The purpose of this study was to describe the frequency and duration of clinical features at the
time of acute human immunodeficiency virus type 1 (HIV-1)disease in 218 patients with documented
symptomatic primary HIV-1 infection. The mean duration of acute HIV-1 disease was 25.1 days
(median, 20.0 days) and did not differ by gender, age, and risk factor. The frequency and mean
duration of clinical features occurring in >50% of patients were as follows: fever, 77.1% and 16.9
days; lethargy, 65.6% and 23.7 days; cutaneous rash, 56.4% and 15 days; myalgia, 54.6% and
17.7 days; and headache, 50.9% and 25.8 days. Only 15.6% of patients presented with a typical
mononucleosis-like illness (MU) defined as fever, pharyngitis or sore throat, and cervical adenopa-
thy, and 10% had no features of an MLI. A meningitis-like syndrome occurred in 20 patients (9.2%).
Acute HIV-1 disease is more diverse than previously reported, and the absence of fever or other
MU features does not rule out acute HIV-1 disease.
Since the first reports of acute HIV type 1 (HIV-l) disease
manifesting as an infectious mononucleosis-like illness (MLI)
[1, 2], physicians have been alert to this diagnosis for popula-
tions at risk. Nevertheless, many cases may go unnoticed be-
cause this illness is not considered in the differential diagnosis,
especially when signs and symptoms are atypical. Therefore,
medical practitioners need to be aware of this illness in ambula-
tory practice [3-6].
The timing of identification of acute HIV-1 disease is crucial
because early treatment reduces the incidence of complications
[7, 8], and individual counseling to prevent further transmission
must be initiated as patients with acute HIV-1 infection may
be particularly contagious [9]. Published studies on acute
HIV-1 disease contain only short descriptions of clinical fea-
tures based on small sample sizes [10-16]. The objective of
our investigation was to describe the frequency and duration
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of clinical features reported during acute HIV-1 infection in a
large cohort of patients.
Patients and Methods
Patients
The patient population consisted of 218 symptomatic sub-
jects enrolled in four prospective studies of HIV-1 seroconver-
sion between 1985 and 1994. One hundred twenty-four patients
were included in two cohorts coordinated by the National Cen-
tre in HIV Epidemiology and Clinical Research in Sydney
(Australia): one cohort was from a prospective study of AIDS
[17] that focused on homosexual men at risk of HIV serocon-
version (67 patients), while the other was from a study that
enrolled persons ofboth genders who were in all risk categories
at the time of acute HIV-l disease (57 patients). Fourteen
Australian patients came from a European-Australian con-
trolled trial on the treatment of primary HIV-1 infection [7].
In addition, 80 European patients were included: 52 from the
Geneva part of the Swiss HIV Cohort Study [18] and another
28 from the European-Australian controlled trial [7] mentioned
above. Each prospective study was approved by the respective
ethics committee.
Biological and Clinical Assessment
The biological inclusion criteria were as follows: (l) the
presence ofp24 antigen in blood with negative or indeterminate
serology (135 patients [62%]); (2) two bands on a western blot,
one of which corresponded to the env gene (glycoprotein (gp)
160, gp 120, or gp 41), with negative or indeterminate serology
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Figure 1. Distribution of the duration of acute HIV-1 disease in
218 patients.
pared by the Mann-Whitney U test, Student's t-test, and one-
way analysis of variance after logarithmic transformation. A
two-tailed P value of <.05 was considered significant. The
statistical analysis was performed with SPSS version 6.0
(SPSS, Chicago) for Windows (Microsoft, Redmond, WA).
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(18 [8%]); or (3) a negative HIV-l screening test followed by
a positive HIV-l test within 1 year (median, 140.0 days) (65
[30%]). The symptoms and signs analyzed were reported by
the patients themselves and/or by their treating physicians at
the time of documented acute HIV-1 disease (criterion 1 or 2)
or within the previous months (median, 65.0 days) before the
first positive HIV-l screening test (criterion 3). The clinical
data were extracted from a review of standardized forms for
data collection. We double-checked the data by examination
of 190 available medical files (private and/or hospital).
We compared the duration of acute HIV-1 disease according
to infection with zidovudine-sensitive (wild-type) HIV-lor
zidovudine-resistant (mutant) HIV-l. The most frequent geno-
type related to zidovudine resistance is a strain with a mutation
at codon 215 of the reverse transcriptase gene [19]. It was
detected by the method proposed by Larder et al. [19]. RNA
was extracted and amplified by selective PCR analysis and
then was reverse transcribed to complementary DNA with
primer RTOI (5'-GTAGAATTCTGTTGAGTCAGATTGG-3').
The genotype determination was done on the first sample avail-
able after the onset of acute HIV-1 disease (median, 25.0 days)
in 99 patients.
Statistical Analysis
Table 1. Characteristics of 218 patients with documented acute
HIV-1 disease.
Categorical variables are described in terms of frequency,
and continuous variables are described as mean, median, and
extreme values. The duration of acute HIV-1 disease was com-
Results
Table 2. Duration of acute HIV-1 disease stratified by age for 218
patients.
23 (4-76)
17 (4-184)
19 (3-94)
21 (5-82)
20 (5-109)
Median (range)
Duration of acute HIV-1 disease (d)*
26.5 (19.9)
22.2 (25.9)
25.1 (19.3)
24.8 (18.0)
28.7 (28.6)
Mean
(±SD)
The characteristics of the patients are listed in table 1, and
the distribution of the duration of acute HIV-1 disease is shown
in figure 1. The average duration of acute HIV-1 disease was
24.8 days for homosexual men and 26.0 days for other patients
(P = .34). There was no significant difference in the duration
between men (24.6 days) and women (32.5 days) (P = .13).
The duration ofacute HIV-1 disease stratified by age is reported
in table 2; there was no difference according to age (P = .8).
Forty-six patients (21%) were hospitalized. Tables 3 and 4
show the frequency and duration of clinical features.
If we define the classical clinical triad of MLI to be fever
(temperature of ~38°C), sore throat or pharyngitis, and cervical
Age (y) at onset of acute
HIV -1 disease (no. of
patients)
~24 (49)
25-29 (51)
30-34 (66)
35-39 (25)
?o40 (27)
Value
31.3 (7.8)
30.6 (18.5-64.8)
25.1 (22.2)
20.0 (3.0-184.0)
138 (63.3)
80 (36.7)
169 (77.5)
9 (4.1)
25 (11.5)
15 (6.9)
204 (93.6)
14 (6.4)
62 (28.4)
54 (24.8)
102 (46.8)
Characteristic
No. (%) of patients with categorical variable
Study population
Australian
European
Gender
Male
Female
Mode of infection (presumed)
Homosexual contact
Intravenous drug use
Heterosexual contact
Other or unknown
Year of onset of acute HIV- I disease
~1987
1988 to 1991
1992 to 30 June 1994
Mean (±SD) for continuous variable
Age (y)
Median (range)
Duration* (d)
Median (range)
* The duration of acute HIV-1 disease was available for 205 patients.
* The difference in the mean duration according to age was not significant
(one-way analysis of variance; P = .80).
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Table 3. Frequency and duration of signs and symptoms reported for ~5% of 218 patients at the time of acute HIV-l disease.
Percentage of patients, sign or Median duration in d
symptom No. (%) of patients Average duration in d (no. of patients) (range)
>50%
Fever (temperature of ;"38°C) 168 (77.1) 16.9 (162) 14.0 (3.0-184.0)
Lethargy 143 (65.6) 23.7 (139) 18.0 (1.0-184.0)
Cutaneous rash 123 (56.4) 15.0 (117) 11.0 (1.0-73.0)
Myalgia 119 (54.6) 17.7 (112) 11.0 (2.0-184.0)
Headache 111 (50.9) 25.8 (108) 13.0 (2.0-continuing*)
>25%-50%
Pharyngitis or sore throat 96 (44.0) 12.2 (90) 8.0 (1.0-51.0)
Cervical adenopathy 85 (39.0) 15.1 (8) 12.0 (3.0-32.0)
Arthralgia 67 (30.7) 22.6 (64) 15.0 (3.0-184.0)
Oral ulcer 63 (28.9) 13.4 (63) 8.0 (1.0-85.0)
Odynophagia 61 (28.0) 16.3 (58) 14.0 (2.0-48.0)
5%-25%
Axillary adenopathy 53 (24.3) 164.1 (6) 13.5 (1.0-continuing*)
Weight loss 52 (23.9) 29.0 (49) 19.0 (3.0-continuing*)
Nausea 52 (23.9) 17.8 (50) 14.0 (2.0-109.0)
Diarrhea 50 (22.9) 12.5 (47) 8.0 (1.0-39.0)
Night sweats 48 (22.0) 14.8 (45) 10.0 (3.0-57.0)
Cough 48 (22.0) 18:4 (48) 12.5 (2.0-184.0)
Anorexia 46 (21.1) 14.6 (44) 10.0 (2.0-68.0)
Inguinal adenopathy 44 (20.2) 8.5 (2) 8.5 (7.0-10.0)
Abdominal pain 42 (19.3) 15.1 (40) 12.0 (1.0-73.0)
Oral candidiasis 37 (17.0) 10.4 (34) 7.5 (1.0-34.0)
Vomiting 27 (12.4) 9.8 (27) 10.0 (1.0-31.0)
Photophobia 26 (11.9) 11.2 (25) 10.0 (2.0-39.0)
Sore eyes 25 (11.5) 13.2 (24) 11.5 (3.0-36.0)
Genital ulcer 15 (6.9) 13.5 (15) 12.0 (3.0-35.0)
Tonsillitis 15 (6.9) 13.3 (13) 10.0 (1.0-41.0)
Depression 14 (6.4) 22.8 (9) 7.0 (3.0-76.0)
Dizziness 12 (5.5) 10.7 (10) 9.5 (2.0-26.0)
* The treating physician considered that the sign or symptom became a chronic feature.
adenopathy [20], 34 patients (15.6%) presented with this clini-
cal picture. Only 26 patients (12%) had an MLI if lethargy
was included in the definition. Twenty-one patients (10%) had
none of these features.
Of the 60 patients with fever but no other MLI features, 31
(52%) had fever plus headache, 15 (25%) had fever plus oral
ulcer, 15 (25%) had fever plus abdominal pain, and 10 (17%)
had fever plus diarrhea. A meningitis-like syndrome (defined
as fever, headache, and stiff neck) occurred in 20 patients
(9.2%).
By contrast, fever was not described in 50 patients (23%).
In these 50 patients, the most frequent clinical features were
sore throat or pharyngitis (23 [46%]), lethargy (22 [44%]),
myalgia (18 [36%)), cutaneous rash (17 [34%D, headache
(17 [34%]), cervical adenopathy (16 [32%]), oral ulcer
(10 [20%]), cough (10 [20%]), and arthralgia (10 [20%)).
There were nine patients infected with zidovudine-resistant
(mutant) HIV-l, and two patients were infected with a mixture
of both wild-type and mutant strains; 88 patients were infected
with a wild-type strain (total number of analyzed cases, 99).
For the 11 patients infected only by a wild-type strain, the
mean duration of acute HIV-l disease was 21.0 days compared
with 26.9 days for the 88 patients infected with a mutant or
mutant and wild-type strains (P = .48). Infections with
HIV-l variants (mutant strain or mutant and wild-type strains)
occurred in 2 patients in 1990, in 3 in 1992, in 4 in 1993, and
in 2 in 1994 (until 30 June). The frequency of clinical features
was not significantly related to infection with zidovudine-resis-
tant HIV-l (mutant strain or mutant and wild-type strains). The
number of patients was too small to analyze further differences
in acute HIV-1 disease between the 11 patients infected with
a mutant strain or mutant and wild-type strains and the 88
infected only by a wild-type strain.
Discussion
The purpose of this descriptive study was to investigate
extensively the clinical features reported at the time of acute
HIV-1 disease in a large cohort of patients. A potential limita-
tion of the study was that the patients differed in terms of risk
factors for HIV-1 infection: 91% of the patients in Australia
were homosexual men compared with 54% of the patients in
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Table 4. Frequency and duration of signs and symptoms reported for <5% of 218 patients at the time of acute HIV-l disease.
Sign or symptom
Sputum production
Occipital adenopathy
Gingivitis
Splenomegaly
Irritability
Peripheral neuropathy
Epitrochlear adenopathy
Thoracic pain
Hepatomegaly
Supraclavicular adenopathy
Dysuria or hematuria
Back pain
Disorientation or confusion
Conjunctivitis
Esophagitis
Encephalitis
Anal ulcer
Psychosis
No. (%) of patients
10 (4.6)
10 (4.6)
10 (4.6)
10 (4.6)
8 (3.7)
8 (3.7)
7 (3.2)
7 (3.2)
7 (3.2)
6 (2.8)
6 (2.8)
5 (2.3)
5 (2.3)
4 (1.8)
4 (1.8)
3 (1.4)
3 (1.4)
2 (0.9)
Average duration in d (no. of patients)
9.8 (8)
NA (NA)
8.1 (10)
17.8 (7)
25.3 (6)
74.8 (6)
NA (NA)
9.4 (7)
7.7 (3)
NA (NA)
4.8 (5)
8.0 (5)
9.8 (4)
4.5 (4)
8.3 (3)
9.6 (3)
NA (NA)
NA (NA)
Median duration in d
(range)
7.0 (3.0-23.0)
NA (NA)
7.0 (3.0-22.0)
8.0 (2.0-48.0)
24.0 (12.0-42.0)
32.0 (13.0-continuing*)
NA (NA)
7.0 (2.0-27.0)
4.0 (2.0-16.0)
NA (NA)
6.0 (3.0-6.0)
7.0 (2.0-16.0)
10.5 (3.0-15.0)
4.0 (3.0-7.0)
8.0 (8.0-9.0)
10.0 (3.0-16.0)
NA (NA)
NA (NA)
NOTE. NA = not available.
* The treating physician considered that the sign or symptom became a chronic feature.
Europe (which also created an imbalance in the sex ratio). We
decided to include patients of both sexes with different risk
factors to facilitate the use of our results by physicians who
work with populations in whom HIV-1 infection does not occur
almost exclusively in one risk group. Until now, all previous
studies except two [7, 15] have been limited to one risk popula-
tion-homosexual and/or bisexual men. Physicians' experi-
ence with acute HIV-1 disease may have affected the accuracy
of the diagnosis, but this circumstance was probably of limited
impact, because clinicians had reached similar levels of clinical
expertise in Australia and Europe when the cohorts were
started.
Some symptoms and signs overlaped (i.e., tonsillitis and
pharyngitis or sore throat), and the reporting of diagnoses was
not completely standardized. For example, in the case oftonsil-
litis, we have to assume that physicians made this diagnosis
when "true" tonsillitis rather than simple pharyngitis was pres-
ent. In any case, tonsillitis and/or pharyngitis or sore throat
occurred in 100 patients (46%), thus confirming the frequent
involvement of the oral cavity during acute HIV-1 illness.
A description as complete as possible of acute HIV-1 disease
gives physicians an understanding of the wide range of diagnos-
tic clinical features that could lead to early therapeutic interven-
tion [7, 8]. The mean and median durations of acute HIV-l
disease were similar to those previously reported [14-16]; for
the first time, we report the absence of a difference in the
duration by gender, age, and risk groups. Because sicker pa-
tients are more likely to be enrolf~d in the cohorts at the time
of acute HIV-1 disease, the clinical description may have been
biased toward more severe disease. Nevertheless, the duration
of some signs and symptoms was only a few days, which
suggests that mild acute HIV-1 disease was represented in our
study.
A possible recall bias may be present for patients enrolled
in the study according to biological inclusion criterion 3. To
quantify this possible bias, we performed an additional fre-
quency analysis restricted to 153 patients for whom the time
relation between symptoms and acute HIV-1 illness was the
strongest (criteria 1 and 2). Among this population, we ob-
served an average increase of 3.7% in the frequency of each
sign or symptom, a finding suggesting that the analysis per-
formed on the whole sample could not have been very biased.
Although MLI is the major clinical syndrome described in
50% to 70% of patients with acute HIV-l disease [5, 14, 16]
and although MLI is emphasized in textbooks [21, 22], some
atypical presentations have occurred, and they have been re-
ported separately [23- 25]. The systematic description ap-
pearing in this study yields a wide spectrum of clinical features
ofthe disease and a relative frequency of an MLI-type presenta-
tion that is low compared with that of less typical presentations.
Thus, if the definition of acute HIV-1 disease as an MLI was
helpful at the beginning of the AIDS epidemic and is still used
[10, 12, 13], our results suggest that the definition of acute
HIV-1 disease should be broadened.
When MLI is absent, fever associated with diarrhea, a cuta-
neous rash, or headaches prompts the diagnosis, especially in
the presence of mucosal ulcers. However, in nearly 25% of
cases, fever is not reported, but a diagnosis may still be made by
eliciting recent risk behavior followed by nonspecific clinical
features of illness. Hence, when an acute infectious disease or
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an unusual dermatologic condition is noted, practrtioners
should consider the possibility of acute HIV-l infection. To
do this rigorously, one needs to know how frequently the main
signs and symptoms of acute HIV-1 disease occur in patients
who do not have acute HIV-1 disease. Our study cannot provide
this information, but clinical experience can nonetheless be
useful.
The more severe features reported during acute HIV-1 dis-
ease were neurological and gastrointestinal. The frequency of
the meningitis-like syndrome, peripheral neuropathy, confu-
sion, and encephalitis was similar to that reported in a French
study [26] and confirmed the early tropism of HIV for the CNS
[27]. Oral candidiasis was observed frequently, and esophagitis
was seen more rarely; both conditions are probably related to
transient depletion and dysfunction of CD4+ cells.
Analysis of each reported symptom or sign by using a stan-
dard questionnaire had the advantage of a greater uniformity
of data collection and perhaps a greater validity compared with
analysis of pooled data from different clinical studies. For ex-
ample, in a review of studies of pooled data, Niu et al. [5]
reported that fever occurred in 96% of their patients (compared
with 77.1% of our patients) and that headache was present in
32% of their patients (compared with 50.9% of our patients);
oral ulcers were not reported (whereas they were present in
28.9% of our patients).
We did not find a difference in the duration of acute infection
with a zidovudine-resistant strain, thus suggesting that primary
infection with an HIV strain with a mutation at codon 215 does
not necessarily itself induce a more aggressive initial infection.
One previous report [28] cited the development of severe im-
munodeficiency in a patient after deliberate injection of blood
containing a mixture of HIV -1 strains. In this case, it is difficult
to assess the relative contributions of inoculum size vs. viral
characteristics to early immunodeficiency.
In conclusion, patients with acute HIV-1 disease present with
a broad array of symptoms and signs, and <20% have the
classical features of an MLI. A febrile syndrome, especially
one associated with gastrointestinal or mucocutaneous features,
occurring in a person at risk of HIV infection should alert
physicians to the possibility of HIV-1 seroconversion. The rea-
sons for the heterogeneous clinical presentation and the relation
of those various clinical presentations to the pathogenesis of
acute HIV-1 infection and to the response to early treatment
remain unclear.
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